Dateline: November 17, 2025 — New York, NY
OS Therapies reported its third-quarter 2025 financial results and issued a comprehensive business update highlighting major regulatory momentum for OST-HER2, its lead listeria-based immunotherapy for pulmonary metastatic osteosarcoma. With strong two-year overall survival data, multiple global regulatory meetings scheduled in December, and a January 2026 BLA and UK MAA filing, the company is entering a decisive phase that may reshape treatment options for this rare, aggressive cancer primarily affecting adolescents and young adults.
Science Significance
OS Therapies continues to advance the science of listeria-based cancer immunotherapies, a platform designed to stimulate potent immune activation against tumor-expressed HER2. The company recently reported statistically significant two-year overall survival outcomes for OST-HER2, including 75% survival vs. 40% historical controls, and 100% survival among patients achieving 12-month event-free survival, demonstrating the therapy’s potential to alter disease trajectory. In addition, biomarker analyses expected imminently could guide post-market confirmatory trials and refine understanding of immune correlates of response. Beyond OST-HER2, emerging Phase 1b data from OST-504 in castration-resistant prostate cancer and plans to seek Platform Designation for the listeria immunotherapy backbone signal expanding scientific relevance across multiple solid tumors.
Regulatory Significance
The company’s regulatory calendar is highly active, with a Type C FDA meeting on December 11, 2025, following a productive End-of-Phase-2 meeting, to finalize expectations for Accelerated Approval based on overall survival and event-free survival endpoints. Parallel UK MHRA pre-MAA and EMA scientific advice meetings will support a synchronized multi-agency submission strategy leveraging Project Orbis. OS Therapies plans to file both its BLA and UK MAA in January 2026, targeting approval by September 30, 2026—qualifying the company for a Priority Review Voucher under its Rare Pediatric Disease Designation, a potentially transformative regulatory asset.
Business Significance
Advertisement
The third quarter reflected forward investment in regulatory and pre-commercial readiness. The company recorded a $6.9 million operating loss, driven largely by preparatory regulatory activities and early commercialization planning for OST-HER2. A $7.8 million warrant exercise inducement strengthened liquidity and enables the company to extend operational runway into late 2026, while delaying product launch to early 2027 strategically preserves capital without materially affecting 2026 revenue expectations due to planned PRV monetization. OS Therapies also transitioned from its equity line of credit to a more flexible ATM financing structure, further optimizing capital strategy ahead of anticipated approvals.
Patients’ Significance
For patients facing recurrent pulmonary metastatic osteosarcoma—a condition with historically poor survival outcomes—OST-HER2 offers a meaningful advance. The therapy’s ability to reduce or delay recurrence has compelling implications for adolescents and young adults, who comprise the majority of affected individuals. Compassionate use requests are rising, particularly from sites participating in the Phase 2b study, and OS Therapies reaffirmed its commitment to supporting patient access where possible. If approved under the Accelerated Approval program, OST-HER2 would represent a first-in-class immunotherapy tailored to this rare disease and may open avenues for HER2-driven cancers beyond osteosarcoma.
Policy Significance
OST-HER2’s regulatory progress reflects broader policy initiatives encouraging innovation in rare pediatric diseases, cross-agency alignment through Project Orbis, and more flexible endpoints for oncology approvals, including overall survival trend modeling. The robust engagement with FDA, MHRA and EMA demonstrates how coordinated global review pathways can accelerate access for high-need patient populations. OS Therapies’ eligibility for a Priority Review Voucher, if approval occurs by September 30, 2026, also underscores policymakers’ commitment to incentivizing development in rare, underserved conditions. The company’s platform ambitions hint at longer-term policy alignment supporting platform-based immunotherapy development.
OS Therapies enters 2026 with strong scientific validation, accelerating regulatory milestones and improved financial visibility. With OST-HER2 positioned for January 2026 BLA and MAA submissions, the next six to twelve months will be transformative for the company and potentially for the osteosarcoma treatment landscape. As regulatory agencies review one of the most promising therapeutic candidates for this rare and devastating disease, OS Therapies is preparing for the next chapter in expanding its listeria-based immunotherapy platform to additional cancers, while maintaining a clear commitment to scientific integrity, patient impact and regulatory excellence.
Source: OS Therapies press release
